Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityTSX:ATD.A / Alimentation Couche-Tard
Institutional Owners0

Institutional Stock Ownership and Shareholders()

Alimentation Couche-Tard (TSX:ATD.A) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Alimentation Couche-Tard (TSX:ATD.A) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

2h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Related News Stories

Logos Capital Q2: Long Industrial Alliance

1h seekingalpha
"Do you have the patience to wait till your mud settles and the water is clear? Can you remain unmoving till the right action arises by itself?" (25-0)

Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of July 16

2018-07-15 seekingalpha
It has been the typical mid-summer lull and dividend increases have slowed significantly. There are two Canadian Dividend All-Stars scheduled to report earnings this week, Exchange Income Fund (OTCPK:EIFZF)[TSX:EIF] and Atrium Mortgage Investment Corp. (OTC:AMIVF)[TSX:AI]. Neither are expected to raise dividends as both have already announced a dividend bump earlier this year. That being said, earnings are scheduled to ramp up, so let’s revisit some of the action from the past number of weeks.

Oakmark International Fund: Second Quarter 2018

2018-07-11 seekingalpha
The Oakmark International Fund declined 5.0% for the quarter ended June 30, 2018, underperforming the MSCI World ex U.S. Index, which declined 0.8% over the same period.

Couche-Tard on lookout for new acquisitions after blockbuster year

2018-07-10 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com

Alimentation Couche-Tard Inc. (ANCUF) CEO Brian Hannasch on Q4 2018 Results - Earnings Call Transcript

2018-07-10 seekingalpha
Good morning. My name is Teresa, and I will be your conference operator today. I would now like to introduce you to Ms. Marie-Noelle Cano, Senior Director, Global Communications of Alimentation Couche-Tard.